HomeEverything
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
← All Stories

Altesa BioSciences Presents New Phase 2 Vapendavir Study Results

Created at 6 Jun · 12:09 AM1 source
IN SHORT

Altesa BioSciences presented new Phase 2 study results for vapendavir at the 2026 American Society for Microbiology (ASM) Microbe Conference. The findings reinforce the drug's potential for preventing rhinovirus-driven COPD exacerbations.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Who's Involved

Altesa BioSciences
Clinical-stage pharmaceutical company presenting study results
American Society for Microbiology (ASM)
Host of the Microbe Conference

↳ Why This Matters

The presentation of these study results at a major microbiology conference highlights progress in developing new treatments for COPD exacerbations, potentially offering a new therapeutic option for patients suffering from these debilitating events.

Key facts

  • Altesa BioSciences presented new Phase 2 study results for vapendavir.
  • The presentation occurred at the 2026 American Society for Microbiology (ASM) Microbe Conference.
  • The study results reinforce the therapeutic potential of vapendavir.
  • Vapendavir is being studied as a targeted approach to preventing rhinovirus-driven COPD exacerbations.

Altesa BioSciences, a clinical-stage pharmaceutical company, presented new findings from a Phase 2 challenge study of its drug candidate, vapendavir, at the 2026 American Society for Microbiology (ASM) Microbe Conference. The clinical findings presented are intended to further reinforce the therapeutic potential of vapendavir. The drug is being investigated as a targeted approach to prevent exacerbations of Chronic Obstructive Pulmonary Disease (COPD) that are driven by rhinovirus infections.

Frequently asked questions

Vapendavir is a drug candidate being developed by Altesa BioSciences. It is being studied for its potential to prevent rhinovirus-driven COPD exacerbations.

The results were presented at the 2026 American Society for Microbiology (ASM) Microbe Conference.

The findings reinforce the therapeutic potential of vapendavir as a targeted treatment for COPD exacerbations caused by rhinovirus.

What Happens Next

01Further clinical trials or regulatory submissions for vapendavir may follow based on these results.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

5 Jun · 4:30 PM
Altesa BioSciences presented Phase 2 vapendavir challenge study results at the 2026 ASM Microbe Conference, reinforcing its therapeutic potential against rhinovirus-driven COPD exacerbations.
PRN | All News Releases via PiQSuite

Sources

T1
Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conferencem.piqsuite.com

Related Stories

NASA Inspector General: Boeing's Starliner Certification Likely Delayed to 2027
1 Jul · 4:16 PM
NASA chief praises Blue Origin progress after launch failure
1 Jul · 8:05 PM
Moody's Flags Quantum Threat to Bitcoin and Digital Assets After Trump Orders
1 Jul · 7:40 PM
T-Mobile sues Broadcom over VMware support for thousands of virtual machines
1 Jul · 9:25 PM
AI Startup Oxmiq Raises $35 Million for Chip Architecture
1 Jul · 1:19 PM